XML 38 R32.htm IDEA: XBRL DOCUMENT v2.4.0.6
Financial Information by Quarter (Unaudited) (Tables)
 12 Months Ended
Dec. 31, 2012
Quarterly Financial Information [Abstract]  
Schedule of quarterly financial information
Financial Information By Quarter (Unaudited)

As previously discussed in Note 3, the Company concluded that the previously issued quarterly periods in the year ended December 31, 2011 included in the Company’s quarterly reports on Forms 10-Q are no longer appropriate to rely upon and have been restated and that the previously issued quarterly periods in the year ended December 31, 2012 have been revised.
 
Three Months Ended
2012
March 31
(Revised)
 
June 30
(Revised)
 
September 30
(Revised)
 
December 31
(Revised)
 
(in thousands, except for per share data)
Revenues
$
1,466

 
$
2,701

 
$
2,290

 
$
2,514

Selling, general and administrative
2,214

 
3,475

 
3,139

 
2,583

Research and development
4,465

 
5,183

 
4,170

 
4,396

Patent preparation fees
336

 
376

 
377

 
794

Operating loss
(5,549
)
 
(6,332
)
 
(5,396
)
 
(5,259
)
Net income (loss)
(4,616
)
 
(3,767
)
 
(3,059
)
 
(2,618
)
Earnings (loss) per share: basic
$
(0.09
)
 
$
(0.07
)
 
$
(0.06
)
 
$
(0.04
)
Earnings (loss) per share: diluted
$
(0.09
)
 
$
(0.07
)
 
$
(0.06
)
 
$
(0.04
)
Schedule of Condensed Balance Sheet
The effects of the revision and restatement on the consolidated balance sheets are summarized in the following table:
 
December 31, 2012
 
December 31, 2011
 
As Originally Reported
 
Adjustments
 
Revised
 
As Originally Reported
 
Adjustments
 
Restated
ASSETS
 
 
 
 
 
 
 
 
 
 
 
Current assets
 
 
 
 
 
 
 
 
 
 
 
Cash and cash equivalents
$
32,017,490

 
 
 
$
32,017,490

 
$
49,256,930

 
 
 
$
49,256,930

Accounts receivable
970,288

 
 
 
970,288

 
2,637,103

 
 
 
2,637,103

Inventory
17,641,922

 
 
 
17,641,922

 
—

 
 
 
—

Prepaid expenses and other current assets
801,149

 
 
 
801,149

 
356,898

 
 
 
356,898

Deferred tax assets, net
33,515,327

 
 
 
33,515,327

 
727,772

 
 
 
727,772

              Total current assets
84,946,176

 
—

 
84,946,176

 
52,978,703

 
—

 
52,978,703

 
 
 
 
 
 
 
 
 
 
 
 
Property, plant and equipment, net
987,869

 
 
 
987,869

 
818,992

 
 
 
818,992

Receivables from long-term contract
3,771,219

 
 
 
3,771,219

 
—

 
 
 
—

Deferred costs
2,841,534

 
 
 
2,841,534

 
250,072

 
 
 
250,072

Goodwill
898,334

 
 
 
898,334

 
898,334

 
 
 
898,334

Other assets
2,181,720

 
 
 
2,181,720

 
285,345

 
 
 
285,345

Deferred tax assets, net
10,209,278

 
 
 
10,209,278

 
35,149,031

 
 
 
35,149,031

              Total assets
$
105,836,130

 
$
—

 
$
105,836,130

 
$
90,380,477

 
$
—

 
$
90,380,477

LIABILITIES AND STOCKHOLDERS' EQUITY
 
 
 
 
 
 
 
 
 
 
 
Current liabilities
 
 
 
 
 
 
 
 
 
 
 
 Accounts payable
$
10,189,917

 
 
 
$
10,189,917

 
$
2,278,316

 
 
 
$
2,278,316

Accrued expenses and other current liabilities
4,283,849

 
 
 
4,283,849

 
4,644,461

 
 
 
4,644,461

Current common stock warrants
287,036

 
46,757

 
333,793

 
—

 
125,841

 
125,841

Current portion of long term debt
954,738

 
 
 
954,738

 
—

 
 
 
—

              Total current liabilities
15,715,540

 
46,757

 
15,762,297

 
6,922,777

 
125,841

 
7,048,618

 
 
 
 
 
 
 
 
 
 
 
 
Deferred revenue
57,052,020

 
 
 
57,052,020

 
41,001,110

 
 
 
41,001,110

Common stock warrants
—

 
657,246

 
657,246

 
622,938

 
789,366

 
1,412,304

Long term debt
3,955,262

 
 
 
3,955,262

 
—

 
 
 
—

Other liabilities
166,303

 
 
 
166,303

 
147,586

 
 
 
147,586

              Total liabilities
76,889,125

 
704,003

 
77,593,128

 
48,694,411

 
915,207

 
49,609,618

Stockholders' equity
 
 
 
 
 
 
 
 
 
 
 
Common stock
5,164

 
 
 
5,164

 
5,164

 
 
 
5,164

Additional paid-in capital
152,340,303

 
15,248,071

 
167,588,374

 
150,551,211

 
15,505,481

 
166,056,692

Accumulated deficit
(123,398,462
)
 
(15,952,074
)
 
(139,350,536
)
 
(108,870,309
)
 
(16,420,688
)
 
(125,290,997
)
              Total stockholders' equity
28,947,005

 
(704,003
)
 
28,243,002

 
41,686,066

 
(915,207
)
 
40,770,859

              Total liabilities and stockholders' equity
$
105,836,130

 
$
—

 
$
105,836,130

 
$
90,380,477

 
$
—

 
$
90,380,477

The effects of the revision and restatement on the unaudited consolidated balance sheets are summarized in the following tables:
 
September 30, 2012
 
September 30, 2011
 
As Originally Reported
Adjustments
Revised
 
As Originally Reported
Adjustments
Restated
Total current assets
42,540,233

 
42,540,233

 
14,538,719

 
14,538,719

Total noncurrent assets
49,511,759

 
49,511,759

 
36,245,375

 
36,245,375

Total assets
92,051,992

 
92,051,992

 
50,784,094

 
50,784,094

Common stock warrants, current
—

235,046

235,046

 
—

233,499

233,499

Common stock warrants, non-current
749,771

1,038,911

1,788,682

 
1,024,987

1,377,733

2,402,720

Other liabilities
59,562,651

—

59,562,651

 
3,779,449

—

3,779,449

Total liabilities
60,312,422

1,273,957

61,586,379

 
4,804,436

1,611,232

6,415,668

Common stock
5,164

 
5,164

 
5,142

 
5,142

Additional paid-in capital
151,944,558

15,248,071

167,192,629

 
149,087,836

15,505,481

164,593,317

Accumulated deficit
(120,210,152
)
(16,522,028
)
(136,732,180
)
 
(103,113,320
)
(17,116,713
)
(120,230,033
)
Total stockholders' equity
31,739,570

(1,273,957
)
30,465,613

 
45,979,658

(1,611,232
)
44,368,426

Total liabilities and stockholders' equity
92,051,992

—

92,051,992

 
50,784,094

—

50,784,094

 
June 30, 2012
 
June 30, 2011
 
As Originally Reported
Adjustments
Revised
 
As Originally Reported
Adjustments
Restated
Total current assets
46,578,955

 
46,578,955

 
17,240,832

 
17,240,832

Total noncurrent assets
46,062,035

 
46,062,035

 
34,727,750

 
34,727,750

Total assets
92,640,990

 
92,640,990

 
51,968,582

 
51,968,582

Common stock warrants, current
—

100,637

100,637

 
—

1,686,760

1,686,760

Common stock warrants, non-current
734,739

1,054,977

1,789,716

 
5,751,035

8,040,268

13,791,303

Other liabilities
57,661,062

—

57,661,062

 
3,268,952

—

3,268,952

Total liabilities
58,395,801

1,155,614

59,551,415

 
9,019,987

9,727,028

18,747,015

Common stock
5,164

 
5,164

 
5,131

 
5,131

Additional paid-in capital
151,509,784

15,248,071

166,757,855

 
146,267,297

15,505,481

161,772,778

Accumulated deficit
(117,269,759
)
(16,403,685
)
(133,673,444
)
 
(103,323,833
)
(25,232,509
)
(128,556,342
)
Total stockholders' equity
34,245,189

(1,155,614
)
33,089,575

 
42,948,595

(9,727,028
)
33,221,567

Total liablities and stockholders' equity
92,640,990

—

92,640,990

 
51,968,582

—

51,968,582

 
March 31, 2012
 
March 31, 2011
 
As Originally Reported
Adjustments
Revised
 
As Originally Reported
Adjustments
Restated
Total current assets
46,636,330

 
46,636,330

 
20,423,847

 
20,423,847

Total noncurrent assets
42,391,291

 
42,391,291

 
2,203,499

 
2,203,499

Total assets
89,027,621

 
89,027,621

 
22,627,346

 
22,627,346

Common stock warrants, current
—

157,014

157,014

 
—

—

—

Common stock warrants, non-current
1,059,751

1,320,909

2,380,660

 
7,790,886

13,487,647

21,278,533

Other liabilities
50,017,901

—

50,017,901

 
3,474,238

—

3,474,238

Total liabilities
51,077,652

1,477,923

52,555,575

 
11,265,124

13,487,647

24,752,771

Common stock
5,164

 
5,164

 
5,038

 
5,038

Additional paid-in capital
150,868,007

15,505,481

166,373,488

 
138,522,944

15,248,732

153,771,676

Accumulated deficit
(112,923,202
)
(16,983,404
)
(129,906,606
)
 
(127,165,760
)
(28,736,379
)
(155,902,139
)
Total stockholders' equity
37,949,969

(1,477,923
)
36,472,046

 
11,362,222

(13,487,647
)
(2,125,425
)
Total liablities and stockholders' equity
89,027,621

—

89,027,621

 
22,627,346

—

22,627,346
Schedule of Condensed Income Statement and Comprehensive Income (Loss)
The effects of the revision and restatement on the consolidated statements of operations and comprehensive income/loss are summarized in the following tables:
 
Year Ended December 31, 2012
 
As Originally Reported
 
Adjustments
 
Revised
Revenues
 
 
 
 
 
       Research and development
$
8,970,835

 
 
 
$
8,970,835

Operating expenses
 
 
 
 
 
       Selling, general and administrative
11,410,131

 
 
 
11,410,131

       Research and development
18,213,036

 
 
 
18,213,036

       Patent preparation fees
1,883,405

 
 
 
1,883,405

   Total operating expenses
31,506,572

 
—

 
31,506,572

   Operating loss
(22,535,737
)
 
—

 
(22,535,737
)
       Decrease (increase) in fair value of common stock warrants
335,902

 
468,614

 
804,516

       Interest expense
(172,993
)
 
 
 
(172,993
)
       Other income, net
522

 
 
 
522

   Loss before benefit from income taxes
(22,372,306
)
 
468,614

 
(21,903,692
)
       Benefit from income taxes
7,844,153

 
 
 
7,844,153

Net income (loss)
$
(14,528,153
)
 
$
468,614

 
$
(14,059,539
)
Basic earnings (loss) per share
$
(0.28
)
 
$
0.01

 
$
(0.27
)
Diluted earnings (loss) per share
$
(0.28
)
 
$
0.01

 
$
(0.27
)
Weighted average shares outstanding: basic
51,639,622

 
—

 
51,639,622

Weighted average shares outstanding: diluted
51,639,622

 
—

 
51,639,622


 
Year Ended December 31, 2011
 
As Originally Reported
 
Adjustments
 
Restated
Revenues
 
 
 
 
 
       Research and development
$
12,725,792

 
 
 
$
12,725,792

Operating expenses
 
 
 
 
 
       Selling, general and administrative
23,931,713

 
 
 
23,931,713

       Research and development
18,367,348

 
 
 
18,367,348

       Patent preparation fees
1,808,168

 
 
 
1,808,168

   Total operating expenses
44,107,229

 
—

 
44,107,229

   Operating loss
(31,381,437
)
 
—

 
(31,381,437
)
       Decrease (increase) in fair value of common stock warrants
8,930,906

 
15,505,403

 
24,436,309

       Other income, net
13,061

 
 
 
13,061

   Loss before benefit from income taxes
(22,437,470
)
 
15,505,403

 
(6,932,067
)
       Benefit from income taxes
36,031,646

 
 
 
36,031,646

Net income (loss)
$
13,594,176

 
$
15,505,403

 
$
29,099,579

Basic earnings (loss) per share
$
0.27

 
$
0.30

 
$
0.57

Diluted earnings (loss) per share
$
0.09

 
$
—

 
$
0.09

Weighted average shares outstanding: basic
50,929,491

 
—

 
50,929,491

Weighted average shares outstanding: diluted
54,061,650

 
—

 
54,061,650


 
Year Ended December 31, 2010
 
As Originally Reported
 
Adjustments
 
Restated
Revenues
 
 
 
 
 
       Research and development
$
19,215,837

 
 
 
$
19,215,837

Operating expenses
 
 
 
 
 
       Selling, general and administrative
8,130,669

 
 
 
8,130,669

       Research and development
22,658,959

 
 
 
22,658,959

       Patent preparation fees
1,148,597

 
 
 
1,148,597

   Total operating expenses
31,938,225

 
—

 
31,938,225

   Operating loss
(12,722,388
)
 
—

 
(12,722,388
)
       Decrease (increase) in fair value of common stock warrants
(15,957,068
)
 
(22,152,962
)
 
(38,110,030
)
       Other income, net
659,292

 
 
 
659,292

   Loss before benefit from income taxes
(28,020,164
)
 
(22,152,962
)
 
(50,173,126
)
       Benefit from income taxes
(175,175
)
 
 
 
(175,175
)
Net income (loss)
$
(28,195,339
)
 
$
(22,152,962
)
 
$
(50,348,301
)
Basic earnings (loss) per share
$
(0.62
)
 
$
(0.50
)
 
$
(1.12
)
Diluted earnings (loss) per share
$
(0.62
)
 
$
(0.50
)
 
$
(1.12
)
Weighted average shares outstanding: basic
45,151,774

 
—

 
45,151,774

Weighted average shares outstanding: diluted
45,151,774

 
—

 
45,151,774

The effects of the revision and restatement on the unaudited consolidated statements of operations and comprehensive income/loss are summarized in the following tables:
 
Three months ended September 30, 2012
 
Nine months ended September 30, 2012
 
As Originally Reported
Adjustments
Revised
 
As Originally Reported
Adjustments
Revised
Revenues
$
2,289,820

 
$
2,289,820

 
$
6,456,736

 
$
6,456,736

Total operating expenses
7,685,619

 
7,685,619

 
23,733,861

 
23,733,861

Operating loss
(5,395,799
)

(5,395,799
)
 
(17,277,125
)

(17,277,125
)
Decrease (increase) in fair value of common stock warrants
(15,032
)
$
(118,343
)
(133,375
)
 
(126,833
)
$
(101,340
)
(228,173
)
Interest expense and other income (loss)
94

 
94

 
330

 
330

Benefit from (provision for) income taxes
2,470,346

 
2,470,346

 
6,063,785

 
6,063,785

Net income (loss)
$
(2,940,391
)
$
(118,343
)
$
(3,058,734
)
 
$
(11,339,843
)
$
(101,340
)
$
(11,441,183
)
Diluted earnings (loss) per share
$
(0.06
)
$
—

$
(0.06
)
 
$
(0.22
)
$
—

$
(0.22
)
Weighted average shares outstanding, diluted
51,639,811

 
51,639,811

 
51,638,648

 
51,638,648

 
Three months ended June 30, 2012
 
Six months ended June 30, 2012
 
As Originally Reported
Adjustments
Revised
 
As Originally Reported
Adjustments
Revised
Revenues
$
2,701,164

 
$
2,701,164

 
$
4,166,916

 
$
4,166,916

Total operating expenses
9,033,527

 
9,033,527

 
16,048,240

 
16,048,240

Operating loss
(6,332,363
)

(6,332,363
)
 
(11,881,324
)

(11,881,324
)
Decrease (increase) in fair value of common stock warrants
325,012

$
579,719

904,731

 
(111,801
)
$
17,003

(94,798
)
Interest expense and other income (loss)
74

 
74

 
236

 
236

Benefit from (provision for) income taxes
1,660,720

 
1,660,720

 
3,593,439

 
3,593,439

Net income (loss)
$
(4,346,557
)
$
579,719

$
(3,766,838
)
 
$
(8,399,450
)
$
17,003

$
(8,382,447
)
Earnings (loss) per share: basic and diluted
$
(0.08
)
$
0.01

$
(0.07
)
 
$
(0.16
)
$
—

$
(0.16
)
Weighted average shares outstanding: basic and diluted
51,638,352

 
51,638,352

 
51,638,061

 
51,638,061

 
Three months ended March 31, 2012
 
As Originally Reported
Adjustments
Revised
Revenues
$
1,465,752

 
$
1,465,752

Total operating expenses
7,014,713

 
7,014,713

Operating loss
(5,548,961
)

(5,548,961
)
Decrease (increase) in fair value of common stock warrants
(436,813
)
$
(562,716
)
(999,529
)
Interest expense and other income (loss)
162

 
162

Benefit from (provision for) income taxes
1,932,719

 
1,932,719

Net income (loss)
$
(4,052,893
)
$
(562,716
)
$
(4,615,609
)
Earnings (loss) per share: basic and diluted
$
(0.08
)
$
(0.01
)
$
(0.09
)
Weighted average shares outstanding: basic and diluted
51,637,770

 
51,637,770

 
Three months ended September 30, 2011
 
Nine months ended September 30, 2011
 
As Originally Reported
Adjustments
Restated
 
As Originally Reported
Adjustments
Restated
Revenues
$
3,577,948

 
$
3,577,948

 
$
7,765,725

 
$
7,765,725

Total operating expenses
9,621,092

 
9,621,092

 
31,378,228

 
31,378,228

Operating loss
(6,043,144
)

(6,043,144
)
 
(23,612,503
)

(23,612,503
)
Decrease (increase) in fair value of common stock warrants
4,726,054

$
8,115,795

12,841,849

 
8,528,863

$
14,809,377

23,338,240

Interest expense and other income (loss)
329

 
329

 
12,429

 
12,429

Benefit from (provision for) income taxes
1,527,275

 
1,527,275

 
34,422,376

 
34,422,376

Net income (loss)
$
210,514

$
8,115,795

$
8,326,309

 
$
19,351,165

$
14,809,377

$
34,160,542

Basic earnings (loss) per share
$
—

$
0.16

$
0.16

 
$
0.38

$
0.29

$
0.67

Diluted earnings (loss) per share
$
—

$
0.11

$
0.11

 
$
0.20

$
—

$
0.20

Weighted average shares outstanding, basic
50,806,284

 
50,806,284

 
50,739,475

 
50,739,475

Weighted average shares outstanding, diluted
51,987,253

 
51,987,253

 
54,234,977

 
54,234,977


 
Three months ended June 30, 2011
 
Six months ended June 30, 2011
 
As Originally Reported
Adjustments
Restated
 
As Originally Reported
Adjustments
Restated
Revenues
$
2,491,056

 
$
2,491,056

 
$
4,187,777

 
$
4,187,777

Total operating expenses
13,598,975

 
13,598,975

 
21,757,135

 
21,757,135

Operating loss
(11,107,919
)

(11,107,919
)
 
(17,569,358
)

(17,569,358
)
Decrease (increase) in fair value of common stock warrants
2,039,851

$
3,503,870

5,543,721

 
3,802,809

$
6,693,582

10,496,391

Interest expense and other income (loss)
2,006

 
2,006

 
12,100

 
12,100

Benefit from (provision for) income taxes
32,907,988

 
32,907,988

 
32,895,101

 
32,895,101

Net income (loss)
$
23,841,926

$
3,503,870

$
27,345,796

 
$
19,140,652

$
6,693,582

$
25,834,234

Basic earnings (loss) per share
$
0.47

$
0.07

$
0.54

 
$
0.38

$
0.13

$
0.51

Diluted earnings (loss) per share
$
0.40

$
—

$
0.40

 
$
0.28

$
—

$
0.28

Weighted average shares outstanding, basic
50,879,599

 
50,879,599

 
50,422,014

 
50,422,014

Weighted average shares outstanding, diluted
54,671,403

 
54,671,403

 
54,507,838

 
54,507,838

 
Three months ended March 31, 2011
 
As Originally Reported
Adjustments
Restated
Revenues
$
1,696,721

 
$
1,696,721

Total operating expenses
8,158,161

 
8,158,161

Operating loss
(6,461,440
)

(6,461,440
)
Decrease (increase) in fair value of common stock warrants
1,762,958

$
3,189,712

4,952,670

Interest expense and other income (loss)
(2,793
)
 
(2,793
)
Net income (loss)
$
(4,701,275
)
$
3,189,712

$
(1,511,563
)
Earnings (loss) per share: basic and diluted
$
(0.09
)
$
0.06

$
(0.03
)
Weighted average shares outstanding: basic and diluted
49,959,345

 
49,959,345